Eric Deneuville

Rennes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis.

Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis.

Journal: CPT: pharmacometrics & systems pharmacology

Published: October 24, 2025

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis.

Elexacaftor/Tezacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients With Cystic Fibrosis.

Journal: Clinical and translational science

Published: March 07, 2025

First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study.

First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: December 15, 2024

Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis.

Beyond the Lung. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Sinonasal Disease in Children With Cystic Fibrosis.

Journal: International forum of allergy & rhinology

Published: November 10, 2024

Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis.

Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis.

Journal: The Journal of clinical endocrinology and metabolism

Published: August 02, 2024

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy.

Journal: Clinical pharmacokinetics

Published: December 19, 2023

Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort.

Epidemiology of childhood interstitial lung disease in France: the RespiRare cohort.

Journal: Thorax

Published: December 17, 2023

Can we decondition TRIKAFTA® tablets for the younger ones?

Can we decondition TRIKAFTA® tablets for the younger ones?

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: July 11, 2023

Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis.

Using chest computed tomography and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis.

Journal: The European respiratory journal

Published: May 11, 2021

Determination of amoxicillin and cotrimoxazole concentrations in sputum of patients with cystic fibrosis.

Determination of amoxicillin and cotrimoxazole concentrations in sputum of patients with cystic fibrosis.

Journal: Biomedical chromatography : BMC

Published: January 22, 2021

Chest physiotherapy enhances detection of Pseudomonas aeruginosa in nonexpectorating children with cystic fibrosis.

Chest physiotherapy enhances detection of Pseudomonas aeruginosa in nonexpectorating children with cystic fibrosis.

Journal: ERJ open research

Published: October 02, 2020

Performance of Molecular Approaches for Aspergillus Detection and Azole Resistance Surveillance in Cystic Fibrosis.

Performance of Molecular Approaches for Aspergillus Detection and Azole Resistance Surveillance in Cystic Fibrosis.

Journal: Frontiers in microbiology

Published: January 17, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026